Skip to content

Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease | Eli Lilly and Company

Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

Table of Contents

Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

Eli Lilly and Company has announced a definitive agreement to acquire Morphic Holding, Inc., a biopharmaceutical company developing oral integrin therapies for the treatment of serious chronic diseases. The acquisition aims to expand Lilly's immunology pipeline with oral integrin therapies, including a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD). The molecule, known as MORF-057, is currently being evaluated in Phase 2 studies in ulcerative colitis and Crohn's disease. The purchase price is set at $57 per share in cash, totaling approximately $3.2 billion. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions. Lilly's acquisition of Morphic reinforces its commitment to developing new therapies in the field of gastroenterology. For more information, visit www.morphictx.com.

Source

Latest